- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Cancer companies do battle
Zmed, a developer of image-guided radiotherapy equipment, has filed suit against Nomos in Boston federal court, alleging patent infringement by Nomos in its recently released ImageSync software on the company's tumor localization system. Zmed's SonArray,
Zmed, a developer of image-guided radiotherapy equipment, has filed suit against Nomos in Boston federal court, alleging patent infringement by Nomos in its recently released ImageSync software on the company's tumor localization system. Zmed's SonArray, an ultrasound-guided adaptive positioning system, uses stereotactic optical guidance and 3D matching software to align the tumor target to the isocenter of the radiotherapy beam. Nomos contends that its new BAT SXi device, which also uses ultrasound to align the radiation beam, does not infringe the Zmed patent, and Nomos has promised to vigorously defend itself against the litigation. Both companies claim victory in a similar court case involving the two last year.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
